Business Context and Reporting Period
This Form 8-K Current Report was filed by Spruce Biosciences, Inc. on June 23, 2021. The filing discloses a corporate governance event regarding the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Kirk Ways, M.D., Ph.D., to the Board of Directors, effective June 23, 2021. Dr. Ways serves as a Class I Director with a term expiring at the 2024 annual meeting of stockholders.
Management Commentary and Compensation Arrangements
Under the Company's non-employee director compensation policy, the following arrangements were established for Dr. Ways:
- Cash Retainer: An annual cash retainer of $35,000 for Board service, pro-rated for calendar year 2021.
- Initial Option Grant: An option to purchase 20,000 shares of common stock granted on the effective date, vesting monthly over a three-year period.
- Annual Option Grants: Automatic annual grants of 10,000 shares on the date of each annual meeting, vesting on the first anniversary of the grant date (or fully vested by the next annual meeting).
- Change in Control: All option grants vest in full upon a change in control, provided Dr. Ways remains in continuous service immediately prior to such event.
Dr. Ways will also enter into the Company's standard Indemnity Agreement for directors. The filing states there are no other transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 20,000-share option grant on potential dilution.
- Review the Company's 2020 Equity Incentive Plan to confirm the definition of "change in control" and associated vesting accelerations.
- Confirm the pro-rated cash retainer amount for the remainder of 2021.
- Check subsequent filings for any changes to the Board composition or compensation policy.